Atanasio Pandiella

List of Publications by Year
in descending order

Version: 2024-02-01

222 papers	10,951 citations	29994 54 h-index	40881 93 g-index
225 all docs	225 docs citations	225 times ranked	14247 citing authors

#	Article	IF	Citations
1	mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer. Molecular Cancer Research, 2022, 20, 1108-1121.	1.5	5
2	Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2022, 41, 106.	3.5	6
3	Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers, 2022, 14, 154.	1.7	30
4	Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 5476.	1.8	2
5	PDCD4 limits prooncogenic neuregulin-ErbB signaling. Cellular and Molecular Life Sciences, 2021, 78, 1799-1815.	2.4	8
6	In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+â€‰breast cancer. Cellular Oncology (Dordrecht), 2021, 44, 569-580.	2.1	16
7	Mapping of Genomic Vulnerabilities in the Post-Translational Ubiquitination, SUMOylation and Neddylation Machinery in Breast Cancer. Cancers, 2021, 13, 833.	1.7	11
8	MZ1 co-operates with trastuzumab in HER2 positive breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 106.	3.5	7
9	Genomic Correlates of DNA Damage in Breast Cancer Subtypes. Cancers, 2021, 13, 2117.	1.7	3
10	Ocoxin oral solution demonstrates antiviral properties in cellular models. Experimental and Therapeutic Medicine, 2021, 22, 1127.	0.8	0
11	Altered proTGFÎ±/cleaved TGFÎ± ratios offer new therapeutic strategies in renal carcinoma. Journal of Experimental and Clinical Cancer Research, 2021, 40, 256.	3.5	1
12	Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer. Npj Precision Oncology, 2021, 5, 78.	2.3	16
13	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. Clinical Cancer Research, 2021, 27, 5096-5108.	3.2	12
14	Generation of Antibody-Drug Conjugate Resistant Models. Cancers, 2021, 13, 4631.	1.7	6
15	Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer. Journal of Experimental and Clinical Cancer Research, 2021, 40, 313.	3.5	6
16	JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Biomedicine and Pharmacotherapy, 2021, 144, 112330.	2.5	4
17	Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates. Frontiers in Immunology, 2021, 12, 786069.	2.2	7
18	Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. Cancer Letters, 2020, 470, 161-169.	3.2	11

#	Article	IF	Citations
19	Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 9034.	1.8	5
20	Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers, 2020, 12, 3271.	1.7	40
21	Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer. Cancer Letters, 2020, 491, 50-59.	3.2	13
22	An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. Pharmaceutics, 2020, 12, 802.	2.0	62
23	Proteolysis targeting chimeras (PROTACs) in cancer therapy. Journal of Experimental and Clinical Cancer Research, 2020, 39, 189.	3.5	36
24	Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1. Cancers, 2020, 12, 2243.	1.7	22
25	Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in tripleâ€negative breast cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 3117-3127.	1.6	12
26	Integrin Î±Î½Î²6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis. Molecular Diagnosis and Therapy, 2020, 24, 143-151.	1.6	6
27	Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond. Trends in Cancer, 2020, 6, 130-146.	3.8	58
28	HER3 targeting with an antibodyâ€drug conjugate bypasses resistance to antiâ€HER2 therapies. EMBO Molecular Medicine, 2020, 12, e11498.	3.3	30
29	HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Research, 2020, 22, 15.	2.2	53
30	Screening and Preliminary Biochemical and Biological Studies of [RuCl(p-cymene)(N,N-bis(diphenylphosphino)-isopropylamine)][BF₄] in Breast Cancer Models. ACS Omega, 2019, 4, 13005-13014.	1.6	7
31	Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome. OncoImmunology, 2019, 8, e1629780.	2.1	34
32	Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. Nanomaterials, 2019, 9, 948.	1.9	12
33	Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis. Frontiers in Oncology, 2019, 9, 1040.	1.3	38
34	Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 383.	3.5	62
35	Prognostic value of receptor tyrosine kinase-like orphan receptor (ROR) family in cancer: A meta-analysis. Cancer Treatment Reviews, 2019, 77, 11-19.	3.4	14
36	Central Role of Cell Cycle Regulation in the Antitumoral Action of Ocoxin. Nutrients, 2019, 11, 1068.	1.7	4

#	Article	IF	Citations
37	Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors. PLoS ONE, 2019, 14, e0209134.	1.1	16
38	TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells. Cancer Letters, 2019, 453, 34-44.	3.2	12
39	Mapping Bromodomains in breast cancer and association with clinical outcome. Scientific Reports, 2019, 9, 5734.	1.6	11
40	Bryoniaï¿½dioica aqueous extract induces apoptosis and G2/M cell cycle arrest in MDAâ€‘MB 231 breast cancer cells. Molecular Medicine Reports, 2019, 20, 73-80.	1.1	2
41	A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors. Frontiers in Immunology, 2019, 10, 2802.	2.2	24
42	MEK5 promotes lung adenocarcinoma. European Respiratory Journal, 2019, 53, 1801327.	3.1	10
43	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. Breast Cancer Research and Treatment, 2019, 174, 693-701.	1.1	34
44	Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors. Frontiers in Oncology, 2019, 9, 1486.	1.3	20
45	The immunoglobulinâ€like domain of neuregulins potentiates ErbB3/HER3 activation and cellular proliferation. Molecular Oncology, 2018, 12, 1061-1076.	2.1	6
46	Resistance to Antibodyâ€“Drug Conjugates. Cancer Research, 2018, 78, 2159-2165.	0.4	136
47	Functional transcriptomic annotation and proteinâ€“protein interaction analysis identify <scp>EZH</scp>2 and <scp>UBE</scp>2C as key upregulated proteins in ovarian cancer. Cancer Medicine, 2018, 7, 1896-1907.	1.3	14
48	Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene. PLoS ONE, 2018, 13, e0207776.	1.1	11
49	Refining Early Antitumoral Drug Development. Trends in Pharmacological Sciences, 2018, 39, 922-925.	4.0	17
50	Transcriptome evolution from breast epithelial cells to basal-like tumors. Oncotarget, 2018, 9, 453-463.	0.8	11
51	Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results. Oncotarget, 2018, 9, 31915-31919.	0.8	14
52	Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer. Breast Cancer Research and Treatment, 2018, 172, 725-732.	1.1	9
53	Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer. International Journal of Oncology, 2018, 53, 113-123.	1.4	10
54	Colorectal cancer and medicinal plants: Principle findings from recent studies. Biomedicine and Pharmacotherapy, 2018, 107, 408-423.	2.5	56

#	Article	IF	Citations
55	Impact of Availability of Companion Diagnostics on the Clinical Development of Anticancer Drugs. Molecular Diagnosis and Therapy, 2017, 21, 337-343.	1.6	4
56	Regulation of the prometastatic neuregulinâ€“<scp>MMP</scp>13 axis by <scp>SRC</scp> family kinases: therapeutic implications. Molecular Oncology, 2017, 11, 1788-1805.	2.1	7
57	Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer. Clinical Cancer Research, 2017, 23, 7006-7019.	3.2	61
58	Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. Molecular Cancer Therapeutics, 2017, 16, 2552-2562.	1.9	44
59	Antitumoral effect of Ocoxin in hepatocellular carcinoma. Oncology Letters, 2017, 14, 1950-1958.	0.8	11
60	Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Scientific Reports, 2017, 7, 17530.	1.6	53
61	Resistance to the Antibodyâ€“Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. Cancer Research, 2017, 77, 4639-4651.	0.4	103
62	ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. Oncogene, 2017, 36, 1733-1744.	2.6	48
63	Neutrophils in cancer: prognostic role and therapeutic strategies. Molecular Cancer, 2017, 16, 137.	7.9	295
64	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. Oncotarget, 2017, 8, 73144-73153.	0.8	24
65	Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors. PLoS ONE, 2017, 12, e0175128.	1.1	28
66	DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer. Oncotarget, 2017, 8, 62834-62841.	0.8	13
67	CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. Oncotarget, 2017, 8, 29679-29698.	0.8	10
68	Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. Oncotarget, 2017, 8, 19478-19490.	0.8	23
69	Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies. Oncotarget, 2017, 8, 22218-22234.	0.8	46
70	Mitotic read-out genes confer poor outcome in luminal A breast cancer tumors. Oncotarget, 2017, 8, 21733-21740.	0.8	18
71	BET inhibitors as novel therapeutic agents in breast cancer. Oncotarget, 2017, 8, 71285-71291.	0.8	33
72	Anticancer activity, phytochemical screening and acute toxicity evaluation of an aqueous extract of Aristolochia longa L.. International Journal of Pharmaceutical and Phytopharmacological Research, 2017, 6, 20.	0.1	8

#	Article	IF	Citations
73	Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer.. Journal of Clinical Oncology, 2017, 35, e17089-e17089.	0.8	0
74	Antitumoral effect of Ocoxin on acute myeloid leukemia. Oncotarget, 2016, 7, 6231-6242.	0.8	17
75	Antiproliferative Effect of Synadenium grantii Hook f. stems (Euphorbiaceae) and a Rare Phorbol Diterpene Ester. International Journal of Toxicology, 2016, 35, 666-671.	0.6	11
76	In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. Molecular Cancer Therapeutics, 2016, 15, 1823-1833.	1.9	23
77	Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. Breast Cancer Research and Treatment, 2016, 156, 1-8.	1.1	10
78	Circulating DNA and Survival in Solid Tumors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 399-406.	1.1	30
79	Breast cancer dissemination promoted by a neuregulin-collagenase 3 signalling node. Oncogene, 2016, 35, 2756-2765.	2.6	18
80	Modulation of cereblon levels by anti-myeloma agents. Leukemia and Lymphoma, 2016, 57, 167-176.	0.6	7
81	Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. PLoS ONE, 2016, 11, e0154789.	1.1	31
82	Multisite phosphorylation of P-Rex1 by protein kinase C. Oncotarget, 2016, 7, 77937-77949.	0.8	7
83	In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget, 2016, 7, 22865-22872.	0.8	21
84	Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies. Oncotarget, 2016, 7, 45042-45051.	0.8	21
85	Targeting the EGF/HER Ligand-Receptor System in Cancer. Current Pharmaceutical Design, 2016, 22, 5887-5898.	0.9	51
86	Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development. Current Cancer Drug Targets, 2016, 17, 48-52.	0.8	2
87	Tumor-Infiltrating Lymphocytes in Breast Cancer: Ready for Prime Time?. Journal of Clinical Oncology, 2015, 33, 1298-1299.	0.8	32
88	In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia, 2015, 29, 705-714.	3.3	72
89	Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer. Nutrition and Cancer, 2015, 67, 1159-1169.	0.9	18
90	The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut, 2015, 64, 1454-1465.	6.1	58

#	Article	IF	Citations
91	Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. Oncotarget, 2015, 6, 27923-27937.	0.8	24
92	Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling. Oncotarget, 2015, 6, 30057-30071.	0.8	15
93	Phospho-kinase profile of colorectal tumors guides in the selection of multi-kinase inhibitors. Oncotarget, 2015, 6, 31272-31283.	0.8	8
94	Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. Oncotarget, 2015, 6, 32856-32867.	0.8	17
95	Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget, 2015, 6, 39538-39549.	0.8	27
96	Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e95219.	1.1	140
97	Achilles' heel of triple negative cancer. Oncoscience, 2014, 1, 115-116.	0.9	2
98	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	3.0	36
99	The Activation of the Sox2 RR2 Pluripotency Transcriptional Reporter in Human Breast Cancer Cell Lines is Dynamic and Labels Cells with Higher Tumorigenic Potential. Frontiers in Oncology, 2014, 4, 308.	1.3	17
100	Genetic and Pharmacologic Evidence That mTOR Targeting Outweighs mTORC1 Inhibition as an Antimyeloma Strategy. Molecular Cancer Therapeutics, 2014, 13, 504-516.	1.9	7
101	Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors. Cancer and Metastasis Reviews, 2014, 33, 295-307.	2.7	5
102	Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis. Cancer Treatment Reviews, 2014, 40, 1048-1055.	3.4	34
103	Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer, 2014, 14, 302.	1.1	49
104	NADPH Oxidases as Therapeutic Targets in Chronic Myelogenous Leukemia. Clinical Cancer Research, 2014, 20, 4014-4025.	3.2	42
105	Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer. Oncogene, 2014, 33, 148-156.	2.6	78
106	Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease. Oncotarget, 2014, 5, 8284-8305.	0.8	43
107	Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget, 2014, 5, 11308-11318.	0.8	40
108	Achillesâ€™ heel of triple negative cancer. Oncoscience, 2014, 1, 763-764.	0.9	2

#	Article	IF	Citations
109	Achilles' heel of triple negative cancer. Oncoscience, 2014, 1, 763-4.	0.9	2
110	ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor. International Journal of Cancer, 2013, 133, 235-246.	2.3	16
111	ERK5/BMK1 Is a Novel Target of the Tumor Suppressor VHL: Implication in Clear Cell Renal Carcinoma. Neoplasia, 2013, 15, 649-IN17.	2.3	53
112	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia, 2013, 27, 430-440.	3.3	112
113	RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Investigational New Drugs, 2013, 31, 200-205.	1.2	11
114	Phosphorylation of P-Rex1 at serine 1169 participates in IGF-1R signaling in breast cancer cells. Cellular Signalling, 2013, 25, 2281-2289.	1.7	16
115	A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers. Oncogene, 2013, 32, 1452-1459.	2.6	9
116	The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treatment Reviews, 2013, 39, 68-76.	3.4	20
117	Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-Initiating Cells that Infiltrate Peritumoral Tissue. Stem Cells, 2013, 31, 1075-1085.	1.4	83
118	Molecular Pathways: P-Rex in Cancer. Clinical Cancer Research, 2013, 19, 4564-4569.	3.2	24
119	HER3 Overexpression and Survival in Solid Tumors: A Meta-analysis. Journal of the National Cancer Institute, 2013, 105, 266-273.	3.0	168
120	Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor. Clinical Cancer Research, 2013, 19, 2677-2687.	3.2	45
121	Targeting HER Receptors in Cancer. Current Pharmaceutical Design, 2013, 19, 808-817.	0.9	39
122	Predominance of mTORC1 over mTORC2 in the Regulation of Proliferation of Ovarian Cancer Cells: Therapeutic Implications. Molecular Cancer Therapeutics, 2012, 11, 1342-1352.	1.9	47
123	CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype. Haematologica, 2012, 97, 1110-1114.	1.7	34
124	Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. International Journal of Oncology, 2012, 41, 1128-1138.	1.4	50
125	Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene, 2012, 31, 1354-1365.	2.6	447
126	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. Leukemia, 2012, 26, 1862-1869.	3.3	73

#	Article	IF	Citations
127	Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects. PLoS ONE, 2012, 7, e34914.	1.1	61
128	Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: Therapeutic implications. International Journal of Cancer, 2012, 131, 244-252.	2.3	42
129	Î²-Lapachone analogs with enhanced antiproliferative activity. European Journal of Medicinal Chemistry, 2012, 53, 264-274.	2.6	34
130	Deficient Spindle Assembly Checkpoint in Multiple Myeloma. PLoS ONE, 2011, 6, e27583.	1.1	33
131	P-Rex1 participates in Neuregulin-ErbB signal transduction and its expression correlates with patient outcome in breast cancer. Oncogene, 2011, 30, 1059-1071.	2.6	92
132	A modular approach to trim cellular targets in anticancer drug discovery. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6641-6645.	1.0	6
133	Overexpression of HER2 signaling to WAVE2â€“Arp2/3 complex activates MMP-independent migration in breast cancer. Breast Cancer Research and Treatment, 2011, 126, 311-318.	1.1	33
134	Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica, 2011, 96, 687-695.	1.7	13
135	Preclinical development of molecular-targeted agents for cancer. Nature Reviews Clinical Oncology, 2011, 8, 200-209.	12.5	145
136	Oncogenic Targets, Magnitude of Benefit, and Market Pricing of Antineoplastic Drugs. Journal of Clinical Oncology, 2011, 29, 2543-2549.	0.8	64
137	Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors. Clinical Cancer Research, 2011, 17, 5546-5552.	3.2	247
138	Transautocrine Signaling by Membrane Neuregulins Requires Cell Surface Targeting, Which Is Controlled by Multiple Domains. Journal of Biological Chemistry, 2011, 286, 24350-24363.	1.6	3
139	In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica, 2010, 95, 794-803.	1.7	144
140	Enhancement of antiproliferative activity by molecular simplification of catalpol. Bioorganic and Medicinal Chemistry, 2010, 18, 2515-2523.	1.4	20
141	Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. Leukemia Research, 2010, 34, 1533-1538.	0.4	22
142	Multisite phosphorylation of Erk5 in mitosis. Journal of Cell Science, 2010, 123, 3146-3156.	1.2	44
143	Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH2 Terminal Kinase Activation and PTEN Upregulation. Clinical Cancer Research, 2010, 16, 4382-4391.	3.2	49
144	Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells. Journal of the National Cancer Institute, 2010, 102, 1432-1446.	3.0	43

#	Article	IF	Citations
145	Do We Have to Change the Way Targeted Drugs Are Developed?. Journal of Clinical Oncology, 2010, 28, e420-e421.	0.8	12
146	Mitotic Arrest Induced by a Novel Family of DNA Topoisomerase II Inhibitors. Journal of Medicinal Chemistry, 2010, 53, 3835-3839.	2.9	18
147	Personalized therapies in the cancer "omics" era. Molecular Cancer, 2010, 9, 202.	7.9	52
148	Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target. PLoS ONE, 2009, 4, e5565.	1.1	99
149	ERK2, but Not ERK1, Mediates Acquired and â€œDe novoâ€•Resistance to Imatinib Mesylate: Implication for CML Therapy. PLoS ONE, 2009, 4, e6124.	1.1	41
150	The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair. Leukemia, 2009, 23, 2265-2274.	3.3	58
151	Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia, 2009, 23, 1515-1527.	3.3	122
152	Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Blood, 2009, 113, 3781-3791.	0.6	78
153	Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer. Current Drug Targets, 2009, 10, 575-576.	1.0	18
154	The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. British Journal of Haematology, 2008, 141, 470-482.	1.2	35
155	New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncology, The, 2008, 9, 1157-1165.	5.1	116
156	Neuregulins and Cancer. Clinical Cancer Research, 2008, 14, 3237-3241.	3.2	95
157	The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype. Haematologica, 2008, 93, 57-66.	1.7	56
158	Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options. Clinical Cancer Research, 2008, 14, 961-970.	3.2	42
159	Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Annals of Oncology, 2008, 19, 1860-1869.	0.6	57
160	The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrology Dialysis Transplantation, 2008, 23, 3403-3411.	0.4	23
161	Aplidin, a Marine Organismâ€“Derived Compound with Potent Antimyeloma Activity In vitro and In vivo. Cancer Research, 2008, 68, 5216-5225.	0.4	98
162	Transforming Growth Factor Î² Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab. Molecular and Cellular Biology, 2008, 28, 5605-5620.	1.1	153

#	Article	IF	Citations
163	Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica, 2008, 93, 851-859.	1.7	31
164	Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2007, 25, 2656-2663.	0.8	53
165	The Extracellular Linker of pro-Neuregulin-Î±2c Is Required for Efficient Sorting and Juxtacrine Function. Molecular Biology of the Cell, 2007, 18, 380-393.	0.9	23
166	Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Annals of Oncology, 2007, 18, 421-430.	0.6	40
167	Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia, 2007, 21, 797-804.	3.3	26
168	Mechanism of apoptosis induced by IFN-Î± in human myeloma cells: Role of Jak1 and Bim and potentiation by rapamycin. Cellular Signalling, 2007, 19, 844-854.	1.7	38
169	Erk5 nuclear location is independent on dual phosphorylation, and favours resistance to TRAIL-induced apoptosis. Cellular Signalling, 2007, 19, 1473-1487.	1.7	29
170	Erk5 is activated and acts as a survival factor in mitosis. Cellular Signalling, 2007, 19, 1964-1972.	1.7	35
171	An update into the pathophysiological role of HER2 in cancer: therapeutic implications. Clinical and Translational Oncology, 2007, 9, 543-544.	1.2	1
172	Antimyeloma Efficacy of Plitidepsin (AplidinÂ®): From Bench to the Bedside.. Blood, 2007, 110, 1178-1178.	0.6	14
173	The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.. Blood, 2007, 110, 1515-1515.	0.6	2
174	Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood, 2006, 107, 3575-3583.	0.6	188
175	Trastuzumab and Antiestrogen Therapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 90-95.	0.6	31
176	Role of metalloproteinases MMP-9 and MT1-MMP in CXCL12-promoted myeloma cell invasion across basement membranes. Journal of Pathology, 2006, 208, 108-118.	2.1	59
177	TGF-Î²1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. Kidney International, 2006, 70, 901-909.	2.6	75
178	Endoglin Modulation of TGF-ÃŸ1-Induced Collagen Synthesis is Dependent on ERK1/2 MAPK Activation. Cellular Physiology and Biochemistry, 2006, 18, 135-142.	1.1	65
179	ERK5 Activates NF-ÎºB in Leukemic T Cells and Is Essential for Their Growth In Vivo. Journal of Immunology, 2006, 177, 7607-7617.	0.4	62
180	The Histone Deacetylase Inhibitor LBH589 Is a Potent Antimyeloma Agent that Overcomes Drug Resistance. Cancer Research, 2006, 66, 5781-5789.	0.4	233

#	Article	IF	Citations
181	Multifunctional role of Erk5 in multiple myeloma. Blood, 2005, 105, 4492-4499.	0.6	82
182	N-terminal cleavage of proTGFÎ± occurs at the cell surface by a TACE-independent activity. Biochemical Journal, 2005, 389, 161-172.	1.7	19
183	Bortezomib is an efficient agent in plasma cell leukemias. International Journal of Cancer, 2005, 114, 665-667.	2.3	59
184	Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma. Clinical Cancer Research, 2005, 11, 3661-3667.	3.2	109
185	Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin. Cancer Research, 2005, 65, 6801-6810.	0.4	63
186	Overexpression of RasN17 Fails to Neutralize Endogenous Ras in MCF7 Breast Cancer Cells. Journal of Biochemistry, 2005, 137, 731-739.	0.9	4
187	Endoglin Expression Regulates Basal and TGF-Î²1-induced Extracellular Matrix Synthesis in Cultured L<sub>6E₉ Myoblasts. Cellular Physiology and Biochemistry, 2004, 14, 301-310.	1.1	46
188	A new simple whole blood flow cytometry-based method for simultaneous identification of activated cells and quantitative evaluation of cytokines released during activation. Laboratory Investigation, 2004, 84, 1387-1398.	1.7	52
189	Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. British Journal of Haematology, 2003, 123, 858-868.	1.2	53
190	Impaired Trafficking and Activation of Tumor Necrosis Factor-Î±-converting Enzyme in Cell Mutants Defective in Protein Ectodomain Shedding. Journal of Biological Chemistry, 2003, 278, 25933-25939.	1.6	44
191	Erk5 Participates in Neuregulin Signal Transduction and Is Constitutively Active in Breast Cancer Cells Overexpressing ErbB2. Molecular and Cellular Biology, 2002, 22, 270-285.	1.1	163
192	Extracellular Signal-regulated Kinase Phosphorylates Tumor Necrosis Factor Î±-converting Enzyme at Threonine 735: A Potential Role in Regulated Shedding. Molecular Biology of the Cell, 2002, 13, 2031-2044.	0.9	273
193	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochemical Journal, 2002, 363, 211.	1.7	43
194	Mitogen-activated protein kinase-dependent and -independent routes control shedding of transmembrane growth factors through multiple secretases. Biochemical Journal, 2002, 363, 211-221.	1.7	51
195	Transforming growth factor-Î²1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L6E9myoblasts. FEBS Letters, 2002, 513, 282-288.	1.3	59
196	A new method for detecting TNF-Î±-secreting cells using direct-immunofluorescence surface membrane stainings. Journal of Immunological Methods, 2002, 264, 77-87.	0.6	30
197	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. Biochemical Journal, 2000, 346, 359.	1.7	19
198	Stimulation of cleavage of membrane proteins by calmodulin inhibitors. Biochemical Journal, 2000, 346, 359-367.	1.7	59

#	Article	IF	Citations
199	Differential Shedding of Transmembrane Neuregulin Isoforms by the Tumor Necrosis Factor-Î±-Converting Enzyme. Molecular and Cellular Neurosciences, 2000, 16, 631-648.	1.0	152
200	Cleavage of the TrkA neurotrophin receptor by multiple metalloproteases generates signalling-competent truncated forms. European Journal of Neuroscience, 1999, 11, 1421-1430.	1.2	49
201	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochemical Journal, 1999, 344, 339-348.	1.7	24
202	Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase. Biochemical Journal, 1999, 344, 339.	1.7	9
203	TrkA receptor ectodomain cleavage generates a tyrosine-phosphorylated cell-associated fragment.. Journal of Cell Biology, 1996, 132, 427-436.	2.3	104
204	Autocrine Regulation of Membrane Transforming Growth Factor-Î± Cleavage. Journal of Biological Chemistry, 1996, 271, 3279-3284.	1.6	69
205	Oleic Acid Blocks Epidermal Growth Factor-Activated Early Intracellular Signals without Altering the Ensuing Mitogenic Response. Experimental Cell Research, 1993, 205, 365-373.	1.2	24
206	Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies. Journal of the National Cancer Institute, 1993, 85, 1327-1333.	3.0	372
207	Membrane-Anchored Growth Factors. Annual Review of Biochemistry, 1993, 62, 515-541.	5.0	641
208	Activated release of membrane-anchored TGF-alpha in the absence of cytosol. Journal of Cell Biology, 1993, 122, 95-101.	2.3	62
209	The cytoplasmic carboxy-terminal amino acid specifies cleavage of membrane TGFÎ± into soluble growth factor. Cell, 1992, 71, 1157-1165.	13.5	136
210	Phosphoinositide Hydrolysis and Ensuing Calcium and Potassium Fluxes: Role in the Action of EGF and Other Growth Factors. Cellular Physiology and Biochemistry, 1992, 2, 196-212.	1.1	2
211	Cleavage of the membrane precursor for transforming growth factor alpha is a regulated process.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 1726-1730.	3.3	219
212	Transforming growth factor-Î±. Biochemical Society Transactions, 1991, 19, 259-262.	1.6	11
213	Thyrotrophin-Releasing Hormone Raises Cytosolic Free Calcium Concentration in Human Adenomatous Somatotrophs and Corticotrophs; Comparison with in vivo Responsiveness to Thyrotrophin-Releasing Hormone in Patients with Acromegaly or Cushing's Disease. Journal of Neuroendocrinology, 1991, 3, 51-56.	1.2	2
214	Voltage-Operated Calcium-Channel Subtypes in Human Neuroblastoma and Rat Pheochromocytoma Cells. Annals of the New York Academy of Sciences, 1989, 560, 249-250.	1.8	1
215	Plasma membrane hyperpolarization and [Ca2+]i increase induced by fibroblast growth factor in NIH-3T3 fibroblasts: Resemblance to early signals generated by platelet-derived growth factor. Biochemical and Biophysical Research Communications, 1989, 163, 1325-1331.	1.0	35
216	Intracellular Calcium Homeostasis in a Human Neuroblastoma Cell Line: Modulation by Depolarization, Cholinergic Receptors, and ?-Latrotoxin. Journal of Neurochemistry, 1988, 50, 1708-1713.	2.1	25

#	Article	IF	Citations
217	Ï‰-Conotoxin binding and effects on calcium channel function in human neuroblastoma and rat pheochromocytoma cell lines. FEBS Letters, 1988, 235, 178-182.	1.3	78
218	Î±1-Adrenergic Stimulation ofin VitroGrowth Hormone Release and Cytosolic Free Ca2+in Rat Somatotrophs*. Endocrinology, 1988, 122, 1419-1425.	1.4	22
219	EGF raises cytosolic Ca2+ in A431 and Swiss 3T3 cells by a dual mechanism. Experimental Cell Research, 1987, 170, 175-185.	1.2	89
220	Protein kinase C-mediated feed back inhibition of the Ca2+ response at the EGF receptor. Biochemical and Biophysical Research Communications, 1987, 149, 145-151.	1.0	23
221	PDGF-induced receptor phosphorylation and phosphoinositide hydrolysis are unaffected by protein kinase C activation in mouse Swiss 3T3 and human skin fibroblasts. Biochemical and Biophysical Research Communications, 1986, 137, 343-350.	1.0	48
222	Early rise of cytosolic Ca2+induced by NGF in PC12 and chromaffin cells. FEBS Letters, 1986, 208, 48-51.	1.3	88